https://scholars.lib.ntu.edu.tw/handle/123456789/620212
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Park K. | en_US |
dc.contributor.author | Tan D.S.W. | en_US |
dc.contributor.author | Su W.-C. | en_US |
dc.contributor.author | Cho B.C. | en_US |
dc.contributor.author | Kim S.-W. | en_US |
dc.contributor.author | Lee K.H. | en_US |
dc.contributor.author | Wang C.-C. | en_US |
dc.contributor.author | Seto T. | en_US |
dc.contributor.author | Huang D.C.-L. | en_US |
dc.contributor.author | Jung H.H. | en_US |
dc.contributor.author | Hsu M.-C. | en_US |
dc.contributor.author | Bogenrieder T. | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.date.accessioned | 2022-09-15T01:08:46Z | - |
dc.date.available | 2022-09-15T01:08:46Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 2666-3643 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122741646&doi=10.1016%2fj.jtocrr.2021.100206&partnerID=40&md5=8538b6bbe9ff63701f22e2c3e48f0595 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/620212 | - |
dc.publisher | Elsevier Inc. | - |
dc.relation.ispartof | JTO Clinical and Research Reports | - |
dc.title | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jtocrr.2021.100206 | - |
dc.identifier.scopus | 2-s2.0-85122741646 | - |
dc.relation.pages | 100206 | - |
dc.relation.journalvolume | 2 | - |
dc.relation.journalissue | 9 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。